Correlation Between Replimune and Achilles Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Replimune and Achilles Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Replimune and Achilles Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Replimune Group and Achilles Therapeutics PLC, you can compare the effects of market volatilities on Replimune and Achilles Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Replimune with a short position of Achilles Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Replimune and Achilles Therapeutics.

Diversification Opportunities for Replimune and Achilles Therapeutics

0.61
  Correlation Coefficient

Poor diversification

The 3 months correlation between Replimune and Achilles is 0.61. Overlapping area represents the amount of risk that can be diversified away by holding Replimune Group and Achilles Therapeutics PLC in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Achilles Therapeutics PLC and Replimune is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Replimune Group are associated (or correlated) with Achilles Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Achilles Therapeutics PLC has no effect on the direction of Replimune i.e., Replimune and Achilles Therapeutics go up and down completely randomly.

Pair Corralation between Replimune and Achilles Therapeutics

Given the investment horizon of 90 days Replimune is expected to generate 1.17 times less return on investment than Achilles Therapeutics. In addition to that, Replimune is 1.25 times more volatile than Achilles Therapeutics PLC. It trades about 0.11 of its total potential returns per unit of risk. Achilles Therapeutics PLC is currently generating about 0.16 per unit of volatility. If you would invest  71.00  in Achilles Therapeutics PLC on September 2, 2024 and sell it today you would earn a total of  37.00  from holding Achilles Therapeutics PLC or generate 52.11% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Replimune Group  vs.  Achilles Therapeutics PLC

 Performance 
       Timeline  
Replimune Group 

Risk-Adjusted Performance

8 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Replimune Group are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite quite conflicting basic indicators, Replimune disclosed solid returns over the last few months and may actually be approaching a breakup point.
Achilles Therapeutics PLC 

Risk-Adjusted Performance

12 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Achilles Therapeutics PLC are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Despite quite weak technical indicators, Achilles Therapeutics disclosed solid returns over the last few months and may actually be approaching a breakup point.

Replimune and Achilles Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Replimune and Achilles Therapeutics

The main advantage of trading using opposite Replimune and Achilles Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Replimune position performs unexpectedly, Achilles Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Achilles Therapeutics will offset losses from the drop in Achilles Therapeutics' long position.
The idea behind Replimune Group and Achilles Therapeutics PLC pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.

Other Complementary Tools

Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
CEOs Directory
Screen CEOs from public companies around the world